Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
0.9312
-0.0222 (-2.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
22,575
Open
0.9000
Bid (Size)
0.9127 (8)
Ask (Size)
0.9600 (1)
Prev. Close
0.9534
Today's Range
0.9000 - 0.9750
52wk Range
0.8500 - 6.000
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
April 10, 2024
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE:
Via
Benzinga
MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023
April 09, 2024
MYNZ stock results show that Mainz Biomed beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
-20.41%
-20.41%
1 Month
-6.88%
-6.88%
3 Month
-14.57%
-14.57%
6 Month
-61.20%
-61.20%
1 Year
-82.69%
-82.69%
More News
Read More
Mainz Biomed Reports Full Year 2023 Financial Results
April 09, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
April 02, 2024
Via
Benzinga
Exposures
COVID-19
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
March 19, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
March 18, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
March 12, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
March 05, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
February 28, 2024
Via
Benzinga
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
February 27, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
February 22, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
February 22, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
February 21, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
February 07, 2024
Via
Benzinga
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
February 06, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
February 02, 2024
Via
News Direct
Topics
Death
Exposures
Death
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
February 01, 2024
Via
Benzinga
Exposures
COVID-19
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
February 01, 2024
Via
Benzinga
Topics
Death
Exposures
Death
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
January 11, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
2024 Marks a New Era Of Pharmaceutical Innovation
January 09, 2024
Via
Benzinga
Exposures
COVID-19
Mainz Biomed Provides Year-End Corporate Review 2023
January 09, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
December 29, 2023
Via
Benzinga
Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study
December 19, 2023
Via
Benzinga
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
December 19, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
December 12, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.